Small molecule HDAC inhibitors like 4PBA36, VX-56336 and AR42 (this study) offer another SMN-independent protective strategy that could be used in concert with SMN2 inducers to maximize therapeutic outcomes in SMA patients. Here, SMN2 is linked to proximal spinal muscular atrophy.